24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. has recently made notable strides in its share performance, opening at $0.81 before dipping to a trading price of $0.764, marking a decrease of around 2.92% from the prior closing price of $0.787. Despite the current selling pressure reflected in a trading volume of 8.08 million shares, liquidity remains robust, indicating strong investor interest. Analysts suggest that the stock may find support at approximately $0.76, while resistance could appear around $0.79. Traders are advised to monitor for any significant volume fluctuations or reversal patterns that may suggest a shift in market dynamics for this volatile stock.

In addition to its stock activity, Hoth Therapeutics has entered into a pivotal exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA) and Emory University. This arrangement provides Hoth exclusive rights to a pioneering patent portfolio centered on “Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions.” This advancement aligns with Hoth’s strategic aim to address the critical public health issue of obesity and its related health complications.

CEO Robb Knie highlighted the importance of this collaboration, stating, “We are honored to collaborate with the VA and Emory University to bring this cutting-edge technology to market.” He termed the agreement a significant milestone for the company’s mission to develop innovative and scientific solutions for addressing obesity.

The comprehensive development plan encompassed in this agreement underscores Hoth’s dedication to translating research into marketable therapies. Furthermore, the company is actively expanding its intellectual property portfolio by pursuing provisional patent protection for HT-001, its leading therapeutic candidate. This initiative reflects Hoth Therapeutics’ commitment to strategic partnerships and ongoing efforts to enhance patient outcomes through novel therapeutic innovations.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.